EP2018864A1 - Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition - Google Patents
Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition Download PDFInfo
- Publication number
- EP2018864A1 EP2018864A1 EP07075639A EP07075639A EP2018864A1 EP 2018864 A1 EP2018864 A1 EP 2018864A1 EP 07075639 A EP07075639 A EP 07075639A EP 07075639 A EP07075639 A EP 07075639A EP 2018864 A1 EP2018864 A1 EP 2018864A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- antibiotics
- group
- inhibitor
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/32—Joints for the hip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
- A61F2/3804—Joints for elbows or knees for elbows
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/40—Joints for shoulders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Definitions
- the invention relates to the use of a pharmaceutical composition according to the preamble of claim 1, a pharmaceutical composition according to the preamble of claim 18, and a substrate comprising a pharmaceutical composition according to the preambles of claims 25 or 27.
- Local application of antibiotics is better suited for therapy of infections of bone and other tissue than systemic antibiotic therapy since by local application higher concentrations of antibiotics can be achieved at the treatment site than by systemic application.
- a prerequisite for a successful local antibiotics therapy is a preceding radical surgical therapy, including debridement of all bone or tissue necroses and excision of all foreign material.
- Local antibiotics carrier known from prior art are bone cements made from polymethyl methacrylate (PMMA), beads made from PMMA, collagen fleeces and bone substituents. These carriers are commercially available with a limited number of antibiotics applied onto them: gentamicin, tobramycin, clindamycin, vancomycin and teicoplanin.
- ineffectiveness is due to biofilm formation and cessation of proliferation of the bacteria to be eliminated.
- intracellular is to be understood with respect to a cell of the host, i. e. of the subject to be treated. Thus, if bacteria are inside a cell of the host, antibiotics being unable to penetrate to the inner of the cell cannot act on the bacteria to be eliminated.
- Staphylococci can survive inside leucocytes. Further, it is known that strains of Staphylococcus aureus showing the so-called Small Colony Variant phenotype can be internalised by keratinocytes and endothelial cells and can persist intracellularly. It was demonstrated that they remain intracellularly inside lysosomes. S. aureus of normal phenotype can also be internalised by endothelial cells, fibroblasts and keratinocytes and can remain intracellularly inside lysosomes.
- Staphylococci can be internalised by primary human osteoblasts and can persist over days and weeks inside osteoblasts without proliferation. After lysis of the osteoblasts, the Staphylococci can proliferate again. Intracellular persistence of Staphylococci and possibly other bacteria in osteoblasts and their potential to remain intracellularly inside lysosomes may play a particular role when looking at bone infections and could be causative for chronic progression of bone infections.
- antibiotics used in prior art for local therapy of infections of bone and other tissue are not suited to treat all these infections successfully.
- local antibiotics carrier containing only gentamicin are ineffective against infections of bacteria showing a Small Colony Variant phenotype and can even induce formation of Small Colony Variant phenotypes. None of the antibiotics used at present for local therapy of infection can eliminate intracellular localized bacteria.
- WO 2006/064517 discloses an antibiotic composition comprising a first antibiotic inhibiting the bacterial protein synthesis and a second antibiotic not inhibiting the bacterial protein synthesis.
- this antibiotic composition is intended to be administered systemically by intravenous or intramuscular application.
- US 5,217,493 discloses an implantable medical device which is coated against biofilm colonization with rifampin and novobiocin, or rifampin and minocycline.
- this coating is not intended to treat an infection but to prevent a bacterial colonization and biofilm formation on the device.
- the local treatment is done at an infection site.
- the tissue to be treated can, e. g., be soft tissue and/or bone tissue (including what is generally denoted as "bone").
- the pharmaceutical composition comprises at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or respective pharmaceutically acceptable derivatives thereof.
- Group A comprises intracellular active antibiotics working as inhibitor of bacterial RNA polymerase, as inhibitor of gyrase or as inhibitor of bacterial protein synthesis.
- Group B comprises extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis or as inhibitor of bacterial protein synthesis or destabilise or rupture the bacterial cell wall directly.
- a combination of at least two antibiotics can be chosen. Such a combination results also in higher efficacy.
- a combination of an intracellular active antibiotic (group A) with an extracellular active antibiotic (group B) may also be chosen.
- antibiotics of group B are not intracellular active, they can inhibit formation of resistances since they act on extracellular bacteria in a bactericidal manner and resistances are only formed in planktonic, proliferating populations of bacteria. Since the extracellular active antibiotics of group B show a different mechanism of action than the antibiotics of group A, parallel resistances can hardly occur.
- the pharmaceutical composition to be used can comprise further additives, dispersants, solvents or carrier substances etc. known per se.
- At least one of the antibiotics chosen should, in an embodiment of the invention, fulfil at least one of the following criteria:
- At least one of the antibiotics chosen fulfils a plurality of the criteria mentioned above. In another embodiment, fulfilment of all of these criteria is achieved. In still another embodiment, a fulfilment of all criteria by all antibiotics chosen is achieved.
- said antibiotics of group A working as inhibitor of bacterial RNA polymerase comprise ansamycins, particularly rifamycins.
- ansamycins particularly rifamycins.
- rifampin, rifabutin, rifapentine or rifamixin may be chosen.
- a pharmaceutical composition containing rifampin is particularly suited in eliminating intracellular Staphylococci, which were shown to be eliminated within 3 days after local administration of an according pharmaceutical composition.
- said antibiotics of group A working as inhibitor of gyrase comprise fluoroquinolones and coumarin antibiotics.
- the fluoroquinolone moxifloxacin as well as the coumarin antibiotic novobiocin are particularly chosen.
- said antibiotics of group A working as inhibitor of bacterial protein synthesis comprise streptogramins like, e. g., quinupristin or dalfopristin. In an embodiment, a combination of quinupristin and dalfopristin is used. It is to be noted that the pharmaceutical composition to be used may contain more than a single antibiotic of each group (and more than two antibiotics of group A if no antibiotic of group B is used) and thus more than two antibiotics in total.
- said antibiotics of group B working as inhibitor of bacterial cell wall synthesis or destabilising and rupturing the cell wall directly comprise glycopeptides, fosfomycin and polypeptides.
- the glycopeptides chosen are vancomycin and teicoplanin.
- the polypeptides chosen are bacitracin, polymyxin B as well as other polymyxins and daptomycin.
- said antibiotics of group B working as inhibitor of bacterial protein synthesis comprise aminoglycosides.
- arbekacin may be chosen.
- An exemplary pharmaceutical composition to be used comprises a rifamycin and an aminoglycoside.
- Another exemplary pharmaceutical composition comprises rifampin and arbekacin; such a composition essentially covers the entire germ spectrum to be eliminated and is effective against problematic bacteria like methicillin-resistant S. aureus (MRSA) or methicillin-resistant S. epidermidis (MRSE). Both antibiotics are effective also against non-proliferating (resting) bacteria and are temperature resistant (heat stable) so that they can be added to a bone cement made of PMMA, to septopal chains, and to spacers for revision operations.
- MRSA methicillin-resistant S. aureus
- MRSE methicillin-resistant S. epidermidis
- Another pharmaceutical composition to be used comprises a rifamycin and fosfomycin.
- Still another pharmaceutical composition comprises rifampin and fosfomycin; such a composition also essentially covers the entire germ spectrum to be eliminated and is also effective against problematic bacteria like MRSA and MRSE.
- Fosfomycin has the further property that it binds reversibly to hydroxyl apatite and thus remains, even after release from a carrier, longer in a bone than other antibiotics. Further, fosfomycin is the smallest antibiotic known and diffuses or penetrates very well through or into bone tissue.
- Still another pharmaceutical composition to be used comprises a rifamycin and a coumarin antibiotic.
- a further exemplary pharmaceutical composition comprises rifampin and novobiocin; such a composition shows a very high effectiveness against gram positive bacteria, in particular also against MRSA and vancomycin resistant enterococci (VRE). Both rifampin and novobiocin are bactericidal against non-proliferating (resting) bacteria.
- a further pharmaceutical composition to be used comprises a rifamycin and a fluoroquinolone.
- Another pharmaceutical composition comprises rifampin and moxifloxacin.
- the pharmaceutical composition to be used further comprises a biofilm formation inhibitor. Every substance reducing or inhibiting at least partially the attachment of germs (especially bacteria) on a surface or the ability of germs to accumulate on a surface to form a biofilm on that surface is considered as biofilm formation inhibitor.
- salicylic acid or a pharmaceutical active derivative or salt thereof is used as biofilm formation inhibitor.
- a combination of salicylic acid and an aminoglycoside may be used.
- Salicylic acid enhances the microbial activity of aminoglycosides against bacteria, especially against E. coli and Klebsiella pneumoniae: Salicylates enter a cell in a protonated form, thereby increasing the membrane potential of the cell. This, in turn, simplifies the uptake of aminoglycosides into the interior of the cell.
- salicylic acid itself shows an effect on bacteria. E. g., growth of encapsulated Klebsiella pneumoniae in the presence of salicylate results in reduced synthesis of capsular polysaccharides. The loss of capsular material exposes the cell surface of K. pneumoniae to the host defence mechanisms, thus shortening the time required for infection clearance.
- Salicylic acid reduces the ability of bacteria to adhere onto surfaces and to form biofilms. Though salicylic acid does not provide 100 % protection against biofilm formation, it supports the effect of antibiotics.
- Acetylsalicylic acid and/or its predominant metabolite, salicylic acid exhibit definable impacts both in vitro and in vivo on microbial virulence phenotypes.
- Bacterial virulence factors help mediate infection by bacteria in a host organism. The following effects have been noted: reduction of adhesion to relevant biomatrices, reduction of capsule production, mitigation of biofilm formation, and diminution of vegetation growth, intravegetation bacterial proliferation, and hematogenous dissemination in experimental infective endocarditis.
- Salicylic acid also upregulates the translation of specific gene loci, including multiple antibiotic-resistance loci. Further, it induces cytoplasmic proteins; and increases quinolone resistance.
- fimbriae colonization factor antigen, P fimbriae and type 1 fimbriae
- S. coli colonization factor antigen
- type 1 fimbriae type 1 fimbriae
- salicylate treatment might prevent infection caused by some strains of fimbriated E. coli Salicylate also limits adherence of E . coli to silastic catheters.
- Chemotaxis in bacteria is modulated through regulation of flagella rotation. This rotation, when counterclockwise, leads to swimming along a linear trajectory and, when clockwise, leads to tumbling.
- Salicylate is recognized as a chemorepellant by the E. coli tsr gene product. This recognition leads to prolonged tumbling of motile E . coli and ultimately causes cells to migrate away from salicylate. Swarming behaviour of E . coli is also inhibited by salicylate in a concentration-dependent manner. Production of the flagellum itself in E . coli is inhibited by growth in the presence of salicylate. This is mediated by inhibiting the production of flagellin, the protein monomer constituting the flagella. It has also been speculated that inhibition of flagella synthesis and motility in E . coli by salicylate is due to reduced synthesis in OmpF synthesis, which may be required for flagella assembly.
- Biofilms consist of microorganisms and other matter encased in a polysaccharide matrix of microbial origin. Growth of Pseudomonas aeruginosa and Staphylococcus epidermidis in the presence of salicylate reduces the production of extracellular polysaccharide required for biofilm formation. The reduction in biofilm formation decreases the ability of these organisms to adhere to contact lenses and medical polymers.
- a component of biofilm production in S. epidermidis is extracellular slime which is composed of a complex mixture of polysaccharides, teichoic acids and proteins. Production of slime-associated proteins and teichoic acids is inhibited in S. epidermidis by salicylate.
- salicylic acid mitigates two distinct virulence phenotypes that are of key relevance for matrix binding (i.e., to fibrinogen and fibronectin) and ⁇ -hemolysin activity. These effects are specifically associated with salicylic acid-mediated reduction in the expression of the respective structural genes (i.e., fnbA, fnbB, and hla). In addition to the suppression of matrix protein binding and cytolytic profiles, enhanced exoenzyme and protein A production occurs in the presence of salicylic acid. These findings raise the likelihood that salicylic acid executed its antimicrobial effects through one or more global regulatory networks rather than a decrease in general gene transcription.
- Global regulon sarA and the global regulon agr are mitigated by salicylic acid, corresponding to the reduced expression in of the hla and fnbA genes in vitro. It should be noted that S. aureus virulence parameters were not completely suppressed by salicylic acid but were reduced, in a drug concentration-dependent manner, by a maximum of approximately 50%.
- the infected tissue to be treated is acutely or chronically infected.
- a combination of an acute and a chronic infection might also be treated.
- a substrate is used as carrier of the pharmaceutical composition when locally treating the tissue infection.
- the substrate can be soaked with the pharmaceutical composition to be used.
- the pharmaceutical composition can be dispersed in a base material of the substrate.
- the pharmaceutical composition can be polymerised with the base material.
- a coating made of a support material in which the pharmaceutical composition is present e. g. in a dispersed form.
- a support material can be, e. g., polylactide.
- the support material with the dispersed pharmaceutical composition is then applied as coating onto the substrate (either directly onto the surface of the latter or onto a layer being already present on that surface or on another layer).
- the substrate comprises a fleece, a fabric, a polymethyl methacrylate, a copolymer of methylmethacrylate and methylacrylate, a resorbable polymer, a metal or a metal alloy (e. g. a Ti6Al4V alloy or another titanium alloy), a ceramic, a bone cement (particularly made from a polymeric material or from calcium phosphate) and/or a bone substitute.
- a metal or a metal alloy e. g. a Ti6Al4V alloy or another titanium alloy
- a ceramic e.g. a Ti6Al4V alloy or another titanium alloy
- a bone cement particularly made from a polymeric material or from calcium phosphate
- the bone cement may be intended to be used for spacer and for revision operations.
- the pharmaceutical composition is dispersed within the Septopal base material.
- the powder is heated to 180°C and filled into forms by injection moulding.
- the pharmaceutical composition is being present all over the base material and can diffuse from the inner parts of a Septopal bead towards the surface, where it may interact with bacteria being present around the Septopal chain.
- the substrate is an implantable prosthesis, wherein joint prostheses and particularly knee, hip, shoulder, elbow prostheses as well as vertebral implants are respective examples. Furthermore, all implants for trauma surgery like screws, plate, etc. may be used as substrate.
- the fleece or fabric comprises a natural or synthetic fibre, which can be biodegradable, wherein polylactide (polylactic acid) is an exemplary material.
- the fleece or fabric comprises collagen, wherein the fleece may consist essentially of collagen. In the latter case, the collagen fleece is also completely biodegradable.
- a pharmaceutical composition having the features of claim 18.
- Such a pharmaceutical composition can be used for the local treatment of a tissue infection at an infection site, whereby further embodiments of such a use are analogous to those explained above and to which in entirety reference is made hereby.
- Such a pharmaceutical composition comprises at least two different antibiotics of group A' or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A' and an antibiotic of group B' or pharmaceutically acceptable derivatives thereof.
- group A' comprises as intracellular active antibiotics ansamycins, particularly rifamycins such as rifampin, rifabutin, rifapentine or rifamixin; fluoroquinolones, particularly moxifloxacin; streptogramins, particularly quinupristin and/or dalfopristin; and coumarin antibiotics, particularly novobiocin.
- Group B' comprises as extracellular active antibiotics glycopeptides, particularly vancomycin or teicoplanin; fosfomycin; polypeptides, particularly bacitracin or polymyxin B; and aminoglycosides, particularly arbekacin. It is to be noted that coumarin antibiotics and glycopeptides cannot be the second antibiotic of a pharmaceutical composition comprising only two antibiotics and comprising an ansamycin as first antibiotic.
- the pharmaceutical composition comprises only a glycopeptide, a polypeptide or fosfomycin as possible antibiotic of group B', but no aminoglycosides are used as antibiotic of group B'. In another embodiment of the invention, no streptogramins are used as antibiotic of group A'.
- the antibiotics are chosen in such a way that either none or all antibiotics in the pharmaceutical composition work as inhibitors of protein synthesis. I. e. either a) only different streptogramins, or a streptogramin and an aminoglycoside may be used or b) no streptogramins and no aminoglycosides may be used at all.
- the pharmaceutical composition comprises a rifamycin and an aminoglycoside, particularly rifampin and arbekacin.
- the pharmaceutical composition comprises a rifamycin and fosfomycin, particularly rifampin and fosfomycin.
- the pharmaceutical composition comprises a rifamycin and a fluoroquinolone, particularly rifampin and moxifloxacin.
- a substrate having the features according to claim 25 or 27.
- a substrate comprises a pharmaceutical composition as described just above or a rifamycin and a coumarin antibiotic, whereby rifampin and novobiocin can be chosen. If the substrate comprises a rifamycin and a coumarin antibiotic, the substrate is necessarily arranged and provided for being used as antibiotic carrier for local antibiotic therapy of an acute or chronic infection of a tissue (bone or soft tissue) of a subject.
- the substrate is arranged and provided for being used as antibiotic carrier for local antibiotic therapy of an acute or chronic infection of a tissue (bone or soft tissue) of a subject in an embodiment of the invention.
- the invention further relates to a method for locally treating a subject with a pharmaceutical composition, the pharmaceutical composition comprising:
- This method may be particularly used for treating a tissue infection of said subject, wherein the tissue may be, e. g., soft tissue and/or bone tissue and/or bone.
- tissue infection might occur due to a surgical operation, particularly due to an operation related to implanting an implant into a human or non-human body.
- the treatment might be applied to a dead or alive human or non-human body.
Abstract
The invention relates to the use of a pharmaceutical composition for the local treatment of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilisation or rupture of the bacterial cell wall. The invention further relates to a related pharmaceutical composition and a substrate carrying a pharmaceutical composition.
Description
- The invention relates to the use of a pharmaceutical composition according to the preamble of claim 1, a pharmaceutical composition according to the preamble of claim 18, and a substrate comprising a pharmaceutical composition according to the preambles of claims 25 or 27.
- Infections of bone and tissue are the severest problem of orthopaedics and surgery, in particular due to increasing operation frequency. 30 % of all bone infections become chronic despite of treatment. Further, many cases are known in which an infection reoccurred after alleged successful earlier treatment. In 3 % of all,cases, amputation is the only remaining option. Systemic treatment with antibiotics is difficult since antibiotics penetrate through bone generally only very poorly and thus concentrations being sufficiently high to eliminate an infection are hardly achievable.
- Local application of antibiotics is better suited for therapy of infections of bone and other tissue than systemic antibiotic therapy since by local application higher concentrations of antibiotics can be achieved at the treatment site than by systemic application. A prerequisite for a successful local antibiotics therapy is a preceding radical surgical therapy, including debridement of all bone or tissue necroses and excision of all foreign material. Local antibiotics carrier known from prior art are bone cements made from polymethyl methacrylate (PMMA), beads made from PMMA, collagen fleeces and bone substituents. These carriers are commercially available with a limited number of antibiotics applied onto them: gentamicin, tobramycin, clindamycin, vancomycin and teicoplanin.
- Though local antibiotics therapy under use of the above-mentioned antibiotics already improved treatment of bone and joint infections, such therapy fails in a significant number of cases (up to 16%). Therapy failure, however, often finally leads to the necessity of an amputation.
- The most important grounds for therapy failure are a) resistances against certain antibiotics, b) ineffectiveness of antibiotics against sessile bacteria, c) intracellular localised bacteria and d) induction of Small Colony Variants. In this context, ineffectiveness according to item b) is due to biofilm formation and cessation of proliferation of the bacteria to be eliminated. Further, in this context, intracellular is to be understood with respect to a cell of the host, i. e. of the subject to be treated. Thus, if bacteria are inside a cell of the host, antibiotics being unable to penetrate to the inner of the cell cannot act on the bacteria to be eliminated.
- It is known for a long while that Staphylococci can survive inside leucocytes. Further, it is known that strains of Staphylococcus aureus showing the so-called Small Colony Variant phenotype can be internalised by keratinocytes and endothelial cells and can persist intracellularly. It was demonstrated that they remain intracellularly inside lysosomes. S. aureus of normal phenotype can also be internalised by endothelial cells, fibroblasts and keratinocytes and can remain intracellularly inside lysosomes.
- Further, it could be shown that Staphylococci can be internalised by primary human osteoblasts and can persist over days and weeks inside osteoblasts without proliferation. After lysis of the osteoblasts, the Staphylococci can proliferate again. Intracellular persistence of Staphylococci and possibly other bacteria in osteoblasts and their potential to remain intracellularly inside lysosomes may play a particular role when looking at bone infections and could be causative for chronic progression of bone infections.
- Though it is still not known exactly whether pseudomonades, streptococci and enterococci can persist in osteoblasts, intracellular persistence of these bacteria could be shown in general. This intracellular persistence was hitherto only thought to be possibly related with chronic progression of other diseases, but since pseudomonades, streptococci and enterococci are frequent pathogens with respect to bone infections, their intracellular persistence might be causative for chronic progression of bone infections.
- Based on this assumption, it is explainable why allegedly successfully treated bone infections can re-outbreak even after years. Inside a host cell the bacteria are protected against numerous antibiotics which cannot penetrate the cell membrane (e. g. penicillins, glycopeptides). Though an acute infection being induced by planktonic (floating) bacteria might be treated with these antibiotics, bacteria can remain intracellularly and cause a re-infection after release from the host cell.
- In prior art, bone and soft tissue infections are treated locally mainly with aminoglycosides (gentamicin, tobramycin) which usually cannot penetrate the cell membrane of host cells. On the other hand, it was reported that aminoglycosides can accumulate in lysosomes of fibroblasts but are inactive due to the low pH of lysosomes.
- Consequently, antibiotics used in prior art for local therapy of infections of bone and other tissue are not suited to treat all these infections successfully. In particular, local antibiotics carrier containing only gentamicin are ineffective against infections of bacteria showing a Small Colony Variant phenotype and can even induce formation of Small Colony Variant phenotypes. None of the antibiotics used at present for local therapy of infection can eliminate intracellular localized bacteria.
-
WO 2006/064517 discloses an antibiotic composition comprising a first antibiotic inhibiting the bacterial protein synthesis and a second antibiotic not inhibiting the bacterial protein synthesis. However, this antibiotic composition is intended to be administered systemically by intravenous or intramuscular application. -
US 5,217,493 discloses an implantable medical device which is coated against biofilm colonization with rifampin and novobiocin, or rifampin and minocycline. However, this coating is not intended to treat an infection but to prevent a bacterial colonization and biofilm formation on the device. - It is an object of the invention to overcome the discussed drawbacks of prior art and to provide a pharmaceutical composition for treating infections of tissue, a substrate carrying such composition, and methods of application of a composition and substrate.
- This object is achieved by a use of a pharmaceutical composition for the local treatment of a tissue infection exhibiting the features of claim 1. In an embodiment of the invention, the local treatment is done at an infection site. The tissue to be treated can, e. g., be soft tissue and/or bone tissue (including what is generally denoted as "bone"). According to the features of claim 1, the pharmaceutical composition comprises at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or respective pharmaceutically acceptable derivatives thereof. Group A comprises intracellular active antibiotics working as inhibitor of bacterial RNA polymerase, as inhibitor of gyrase or as inhibitor of bacterial protein synthesis. Group B comprises extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis or as inhibitor of bacterial protein synthesis or destabilise or rupture the bacterial cell wall directly.
- In order to circumvent resistances against the antibiotics used, particularly in long-term treatments, a combination of at least two antibiotics can be chosen. Such a combination results also in higher efficacy. Though it is generally considerable to only use intracellular active antibiotics, a combination of an intracellular active antibiotic (group A) with an extracellular active antibiotic (group B) may also be chosen. Though antibiotics of group B are not intracellular active, they can inhibit formation of resistances since they act on extracellular bacteria in a bactericidal manner and resistances are only formed in planktonic, proliferating populations of bacteria. Since the extracellular active antibiotics of group B show a different mechanism of action than the antibiotics of group A, parallel resistances can hardly occur.
- The pharmaceutical composition to be used can comprise further additives, dispersants, solvents or carrier substances etc. known per se.
- In order to achieve good results in treating infections of bone and other tissue, at least one of the antibiotics chosen should, in an embodiment of the invention, fulfil at least one of the following criteria:
- a) It should penetrate the cell membrane of the host cell (i. e. the cell of the subject to be treated inside which the bacteria to be eliminated are located).
- b) It should be able to reach the inside of the lysosomes of the host cell.
- c) It should be active at low pH (particularly at that pH being present in lysosomes, i. e. ca. pH 4 to pH 5).
- d) It should have a bactericidal activity.
- e) It should show its bactericidal activity also against non-proliferating bacteria.
- In an embodiment of the invention, at least one of the antibiotics chosen fulfils a plurality of the criteria mentioned above. In another embodiment, fulfilment of all of these criteria is achieved. In still another embodiment, a fulfilment of all criteria by all antibiotics chosen is achieved.
- In an embodiment of the invention said antibiotics of group A working as inhibitor of bacterial RNA polymerase comprise ansamycins, particularly rifamycins. Particularly, rifampin, rifabutin, rifapentine or rifamixin may be chosen. A pharmaceutical composition containing rifampin is particularly suited in eliminating intracellular Staphylococci, which were shown to be eliminated within 3 days after local administration of an according pharmaceutical composition.
- In a further embodiment of the invention said antibiotics of group A working as inhibitor of gyrase comprise fluoroquinolones and coumarin antibiotics. The fluoroquinolone moxifloxacin as well as the coumarin antibiotic novobiocin are particularly chosen.
- In an embodiment of the invention, said antibiotics of group A working as inhibitor of bacterial protein synthesis comprise streptogramins like, e. g., quinupristin or dalfopristin. In an embodiment, a combination of quinupristin and dalfopristin is used. It is to be noted that the pharmaceutical composition to be used may contain more than a single antibiotic of each group (and more than two antibiotics of group A if no antibiotic of group B is used) and thus more than two antibiotics in total.
- In an embodiment of the invention, said antibiotics of group B working as inhibitor of bacterial cell wall synthesis or destabilising and rupturing the cell wall directly comprise glycopeptides, fosfomycin and polypeptides. In an embodiment of the invention, the glycopeptides chosen are vancomycin and teicoplanin. In the same or another embodiment of the invention, the polypeptides chosen are bacitracin, polymyxin B as well as other polymyxins and daptomycin.
- In an embodiment of the invention, said antibiotics of group B working as inhibitor of bacterial protein synthesis comprise aminoglycosides. In this context, particularly arbekacin may be chosen.
- An exemplary pharmaceutical composition to be used comprises a rifamycin and an aminoglycoside. Another exemplary pharmaceutical composition comprises rifampin and arbekacin; such a composition essentially covers the entire germ spectrum to be eliminated and is effective against problematic bacteria like methicillin-resistant S. aureus (MRSA) or methicillin-resistant S. epidermidis (MRSE). Both antibiotics are effective also against non-proliferating (resting) bacteria and are temperature resistant (heat stable) so that they can be added to a bone cement made of PMMA, to septopal chains, and to spacers for revision operations.
- Another pharmaceutical composition to be used comprises a rifamycin and fosfomycin. Still another pharmaceutical composition comprises rifampin and fosfomycin; such a composition also essentially covers the entire germ spectrum to be eliminated and is also effective against problematic bacteria like MRSA and MRSE. Fosfomycin has the further property that it binds reversibly to hydroxyl apatite and thus remains, even after release from a carrier, longer in a bone than other antibiotics. Further, fosfomycin is the smallest antibiotic known and diffuses or penetrates very well through or into bone tissue.
- Still another pharmaceutical composition to be used comprises a rifamycin and a coumarin antibiotic. A further exemplary pharmaceutical composition comprises rifampin and novobiocin; such a composition shows a very high effectiveness against gram positive bacteria, in particular also against MRSA and vancomycin resistant enterococci (VRE). Both rifampin and novobiocin are bactericidal against non-proliferating (resting) bacteria.
- A further pharmaceutical composition to be used comprises a rifamycin and a fluoroquinolone. Another pharmaceutical composition comprises rifampin and moxifloxacin.
- In an embodiment of the invention, the pharmaceutical composition to be used further comprises a biofilm formation inhibitor. Every substance reducing or inhibiting at least partially the attachment of germs (especially bacteria) on a surface or the ability of germs to accumulate on a surface to form a biofilm on that surface is considered as biofilm formation inhibitor.
- In an embodiment of the invention, salicylic acid or a pharmaceutical active derivative or salt thereof is used as biofilm formation inhibitor. Particularly, a combination of salicylic acid and an aminoglycoside may be used. Salicylic acid enhances the microbial activity of aminoglycosides against bacteria, especially against E. coli and Klebsiella pneumoniae: Salicylates enter a cell in a protonated form, thereby increasing the membrane potential of the cell. This, in turn, simplifies the uptake of aminoglycosides into the interior of the cell.
- But even salicylic acid itself shows an effect on bacteria. E. g., growth of encapsulated Klebsiella pneumoniae in the presence of salicylate results in reduced synthesis of capsular polysaccharides. The loss of capsular material exposes the cell surface of K. pneumoniae to the host defence mechanisms, thus shortening the time required for infection clearance. Salicylic acid reduces the ability of bacteria to adhere onto surfaces and to form biofilms. Though salicylic acid does not provide 100 % protection against biofilm formation, it supports the effect of antibiotics.
- Acetylsalicylic acid and/or its predominant metabolite, salicylic acid, exhibit definable impacts both in vitro and in vivo on microbial virulence phenotypes. Bacterial virulence factors help mediate infection by bacteria in a host organism. The following effects have been noted: reduction of adhesion to relevant biomatrices, reduction of capsule production, mitigation of biofilm formation, and diminution of vegetation growth, intravegetation bacterial proliferation, and hematogenous dissemination in experimental infective endocarditis. Salicylic acid also upregulates the translation of specific gene loci, including multiple antibiotic-resistance loci. Further, it induces cytoplasmic proteins; and increases quinolone resistance.
- The synthesis of some types of fimbriae in E. coli (colonization factor antigen, P fimbriae and type 1 fimbriae) are reduced following growth in the presence of salicylate. Because fimbriae play a critical role in the attachment of E. coli to epithelial surfaces, salicylate treatment might prevent infection caused by some strains of fimbriated E. coli Salicylate also limits adherence of E. coli to silastic catheters.
- Chemotaxis in bacteria is modulated through regulation of flagella rotation. This rotation, when counterclockwise, leads to swimming along a linear trajectory and, when clockwise, leads to tumbling. Salicylate is recognized as a chemorepellant by the E. coli tsr gene product. This recognition leads to prolonged tumbling of motile E. coli and ultimately causes cells to migrate away from salicylate. Swarming behaviour of E. coli is also inhibited by salicylate in a concentration-dependent manner. Production of the flagellum itself in E. coli is inhibited by growth in the presence of salicylate. This is mediated by inhibiting the production of flagellin, the protein monomer constituting the flagella. It has also been speculated that inhibition of flagella synthesis and motility in E. coli by salicylate is due to reduced synthesis in OmpF synthesis, which may be required for flagella assembly.
- Biofilms consist of microorganisms and other matter encased in a polysaccharide matrix of microbial origin. Growth of Pseudomonas aeruginosa and Staphylococcus epidermidis in the presence of salicylate reduces the production of extracellular polysaccharide required for biofilm formation. The reduction in biofilm formation decreases the ability of these organisms to adhere to contact lenses and medical polymers. A component of biofilm production in S. epidermidis is extracellular slime which is composed of a complex mixture of polysaccharides, teichoic acids and proteins. Production of slime-associated proteins and teichoic acids is inhibited in S. epidermidis by salicylate.
- In case of S. aureus, salicylic acid mitigates two distinct virulence phenotypes that are of key relevance for matrix binding (i.e., to fibrinogen and fibronectin) and α-hemolysin activity. These effects are specifically associated with salicylic acid-mediated reduction in the expression of the respective structural genes (i.e., fnbA, fnbB, and hla). In addition to the suppression of matrix protein binding and cytolytic profiles, enhanced exoenzyme and protein A production occurs in the presence of salicylic acid. These findings raise the likelihood that salicylic acid executed its antimicrobial effects through one or more global regulatory networks rather than a decrease in general gene transcription. Global regulon sarA and the global regulon agr are mitigated by salicylic acid, corresponding to the reduced expression in of the hla and fnbA genes in vitro. It should be noted that S. aureus virulence parameters were not completely suppressed by salicylic acid but were reduced, in a drug concentration-dependent manner, by a maximum of approximately 50%.
- In an embodiment of the invention, the infected tissue to be treated is acutely or chronically infected. A combination of an acute and a chronic infection (the acute infection overlying the chronic infection) might also be treated.
- In another embodiment of the invention, a substrate is used as carrier of the pharmaceutical composition when locally treating the tissue infection. In one embodiment of the invention, the substrate can be soaked with the pharmaceutical composition to be used. In another embodiment of the invention, the pharmaceutical composition can be dispersed in a base material of the substrate. In still another embodiment, the pharmaceutical composition can be polymerised with the base material. Thus, it is possible to coat the substrate with the pharmaceutical composition and/or to incorporate the pharmaceutical composition into the substrate.
- Within the scope of the present invention is also a coating made of a support material in which the pharmaceutical composition is present (e. g. in a dispersed form). Such support material can be, e. g., polylactide. The support material with the dispersed pharmaceutical composition is then applied as coating onto the substrate (either directly onto the surface of the latter or onto a layer being already present on that surface or on another layer).
- In an embodiment of the invention, the substrate comprises a fleece, a fabric, a polymethyl methacrylate, a copolymer of methylmethacrylate and methylacrylate, a resorbable polymer, a metal or a metal alloy (e. g. a Ti6Al4V alloy or another titanium alloy), a ceramic, a bone cement (particularly made from a polymeric material or from calcium phosphate) and/or a bone substitute. Thus, Septopal chains (consisting mainly of a copolymer of methylmethacrylate and methylacrylate as well as glycine and a specific pharmaceutical composition to be administered) as local antibiotics carrier are a possible substrate. Further, the bone cement may be intended to be used for spacer and for revision operations.
- In case of Septopal chains, the following mode of use is possible: firstly, the pharmaceutical composition is dispersed within the Septopal base material. The powder is heated to 180°C and filled into forms by injection moulding. The pharmaceutical composition is being present all over the base material and can diffuse from the inner parts of a Septopal bead towards the surface, where it may interact with bacteria being present around the Septopal chain.
- In another embodiment (particularly regarding revision operations), the substrate is an implantable prosthesis, wherein joint prostheses and particularly knee, hip, shoulder, elbow prostheses as well as vertebral implants are respective examples. Furthermore, all implants for trauma surgery like screws, plate, etc. may be used as substrate.
- In an embodiment of the invention the fleece or fabric comprises a natural or synthetic fibre, which can be biodegradable, wherein polylactide (polylactic acid) is an exemplary material. In another embodiment the fleece or fabric comprises collagen, wherein the fleece may consist essentially of collagen. In the latter case, the collagen fleece is also completely biodegradable.
- The object of the invention is also achieved by a pharmaceutical composition having the features of claim 18. Such a pharmaceutical composition can be used for the local treatment of a tissue infection at an infection site, whereby further embodiments of such a use are analogous to those explained above and to which in entirety reference is made hereby.
- Such a pharmaceutical composition comprises at least two different antibiotics of group A' or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A' and an antibiotic of group B' or pharmaceutically acceptable derivatives thereof. In this case, group A' comprises as intracellular active antibiotics ansamycins, particularly rifamycins such as rifampin, rifabutin, rifapentine or rifamixin; fluoroquinolones, particularly moxifloxacin; streptogramins, particularly quinupristin and/or dalfopristin; and coumarin antibiotics, particularly novobiocin. Group B' comprises as extracellular active antibiotics glycopeptides, particularly vancomycin or teicoplanin; fosfomycin; polypeptides, particularly bacitracin or polymyxin B; and aminoglycosides, particularly arbekacin. It is to be noted that coumarin antibiotics and glycopeptides cannot be the second antibiotic of a pharmaceutical composition comprising only two antibiotics and comprising an ansamycin as first antibiotic.
- In an embodiment of the invention, the pharmaceutical composition comprises only a glycopeptide, a polypeptide or fosfomycin as possible antibiotic of group B', but no aminoglycosides are used as antibiotic of group B'. In another embodiment of the invention, no streptogramins are used as antibiotic of group A'.
- In an embodiment of the invention, the antibiotics are chosen in such a way that either none or all antibiotics in the pharmaceutical composition work as inhibitors of protein synthesis. I. e. either a) only different streptogramins, or a streptogramin and an aminoglycoside may be used or b) no streptogramins and no aminoglycosides may be used at all.
- In an alternative embodiment of the invention, the pharmaceutical composition comprises a rifamycin and an aminoglycoside, particularly rifampin and arbekacin.
- In another embodiment of the invention, the pharmaceutical composition comprises a rifamycin and fosfomycin, particularly rifampin and fosfomycin.
- In still another embodiment of the invention, the pharmaceutical composition comprises a rifamycin and a fluoroquinolone, particularly rifampin and moxifloxacin.
- The object of the invention is further achieved by a substrate having the features according to claim 25 or 27. Such a substrate comprises a pharmaceutical composition as described just above or a rifamycin and a coumarin antibiotic, whereby rifampin and novobiocin can be chosen. If the substrate comprises a rifamycin and a coumarin antibiotic, the substrate is necessarily arranged and provided for being used as antibiotic carrier for local antibiotic therapy of an acute or chronic infection of a tissue (bone or soft tissue) of a subject.
- In other cases, the substrate is arranged and provided for being used as antibiotic carrier for local antibiotic therapy of an acute or chronic infection of a tissue (bone or soft tissue) of a subject in an embodiment of the invention.
- With respect to further embodiments of the substrate, reference is made to the detailed description given above, which is analogously applicable also in the present context.
- The invention further relates to a method for locally treating a subject with a pharmaceutical composition, the pharmaceutical composition comprising:
- at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof or
- an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof, wherein
- group A comprises intracellular active antibiotics working as
- inhibitor of bacterial RNA polymerase,
- inhibitor of gyrase or
- inhibitor of bacterial protein synthesis and
- group B comprises extracellular active antibiotics working
- as inhibitor of bacterial cell wall synthesis,
- as inhibitor of bacterial protein synthesis or
- by direct destabilisation or rupture of the bacterial cell wall.
- group A comprises intracellular active antibiotics working as
- This method may be particularly used for treating a tissue infection of said subject, wherein the tissue may be, e. g., soft tissue and/or bone tissue and/or bone. These infections might occur due to a surgical operation, particularly due to an operation related to implanting an implant into a human or non-human body. Thus, the treatment might be applied to a dead or alive human or non-human body.
- With respect to further embodiments of this aspect of the invention, reference is made the explanations given above which are analogously applicable for said method, particularly regarding the substrate to be used and the antibiotics to be chosen.
Claims (30)
- Use of a pharmaceutical composition for the local treatment of a tissue infection, the pharmaceutical composition comprising:- at least two different antibiotics of group A or pharmaceutically acceptable derivatives or salts thereof or- an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives or salts thereof, whereingroup A comprises intracellular active antibiotics working as- inhibitor of bacterial RNA polymerase,- inhibitor of gyrase or- inhibitor of bacterial protein synthesis andgroup B comprises extracellular active antibiotics working- as inhibitor of bacterial cell wall synthesis,- as inhibitor of bacterial protein synthesis or- by direct destabilisation or rupture of the bacterial cell wall.
- Use according to claim 1, characterised in that said antibiotics of group A working as inhibitor of bacterial RNA polymerase comprise ansamycins, particularly rifamycins such as rifampin, rifabutin, rifapentine or rifamixin.
- Use according to claim 1 or 2, characterised in that said antibiotics of group A working as inhibitor of gyrase comprise fluoroquinolones, particularly moxifloxacin, and coumarin antibiotics, particularly novobiocin.
- Use according to any of the preceding claims, characterised in that said antibiotics of group A working as inhibitor of bacterial protein synthesis comprise streptogramins, particularly quinupristin and/or dalfopristin.
- Use according to any of the preceding claims, characterised in that said antibiotics of group B working as inhibitor of bacterial cell wall synthesis comprise glycopeptides, particularly vancomycin or teicoplanin, fosfomycin and polypeptides, particularly bacitracin.
- Use according to any of the preceding claims, characterised in that said antibiotics of group B working by direct destabilisation or rupture of the bacterial cell wall comprise polypeptides, particularly polymycin B, other polymyxins and daptomycin.
- Use according to any of the preceding claims, characterised in that said antibiotics of group B working as inhibitor of bacterial protein synthesis comprise aminoglycosides, particularly arbekacin.
- Use according to any of the preceding claims, characterised in that it comprises a rifamycin and an aminoglycoside, particularly rifampin and arbekacin.
- Use according to any of the preceding claims, characterised in that it comprises a rifamycin and fosfomycin, particularly rifampin and fosfomycin.
- Use according to any of the preceding claims, characterised in that it comprises a rifamycin and a coumarin antibiotic, particularly rifampin and novobiocin.
- Use according to any of the preceding claims, characterised in that it comprises a rifamycin and a fluoroquinolone, particularly rifampin and moxifloxacin.
- Use according to any of the preceding claims, characterised in that it said pharmaceutical composition further comprises a biofilm formation inhibitor, particularly salicylic acid or a pharmaceutically acceptable derivate or salt thereof.
- Use according to any of the preceding claims, characterised in that the infected tissue to be treated is acutely or chronically infected.
- Use according to any of the preceding claims, characterised in that a substrate is used as carrier of the pharmaceutical composition.
- Use according to claim 14, characterised in that the substrate comprises a fleece, a fabric, polymethyl methacrylate, a copolymer of methylmethacrylate and methylacrylate, a biodegradable polymer, a metal, a ceramic, a bone cement and/or a bone substitute.
- Use according to claim 15, characterised in that the fleece or the fabric comprises a natural or synthetic fibre, particularly polylactide, and/or collagen.
- Use according to any of claims 14 to 16, characterised in that the substrate is an implantable prosthesis, in particular a hip prosthesis, a shoulder prosthesis, an elbow prosthesis, a knee prosthesis or a vertebral implant or an implant for trauma surgery.
- Pharmaceutical composition, comprising- at least two different antibiotics of group A' or pharmaceutically acceptable derivatives or salts thereof or- an antibiotic of group A' and at least one antibiotic of group B' or pharmaceutically acceptable derivatives or salts thereof, whereingroup A' comprises- ansamycins, particularly rifamycins such as rifampin, rifabutin, rifapentine or rifamixin,- fluoroquinolones, particularly moxifloxacin,- streptogramins, particularly quinupristin and/or dalfopristin,- coumarin antibiotics, particularly novobiocin, andgroup B' compriseswherein- glycopeptides, particularly vancomycin or teicoplanin,- fosfomycin,- polypeptides, particularly bacitracin, polymyxin B, other polymyxins, and daptomycin,- aminoglycosides, particularly arbekacin,- coumarin antibiotics and glycopeptides cannot be the second antibiotic of a composition comprising only two antibiotics and comprising an ansamycin as first antibiotic.
- Pharmaceutical composition according to claim 18, characterised in that only a glycopeptide, a polypeptide or fosfomycin are used as antibiotic of group B'.
- Pharmaceutical composition according to claim 18, characterised in that the antibiotics are chosen in such a way that either none or all antibiotics in the pharmaceutical composition work as inhibitors of protein synthesis.
- Pharmaceutical composition according to claim 18, characterised in that it comprises a rifamycin and an aminoglycoside, particularly rifampin and arbekacin.
- Pharmaceutical composition according to any of claims 18 to 21, characterised in that it comprises a rifamycin and fosfomycin, particularly rifampin and fosfomycin.
- Pharmaceutical composition according to any of claims 18 to 22, characterised in that it comprises a rifamycin and a fluoroquinolone, particularly rifampin and moxifloxacin.
- Pharmaceutical composition according to any of claims 18 to 23, characterised in that it further comprises a biofilm formation inhibitor, particularly salicylic acid or a pharmaceutically acceptable derivate or salt thereof.
- Substrate for medical purposes, comprising a pharmaceutical composition according to any of claims 18 to 23.
- Substrate according to claim 25, characterised in that it is arranged and provided for being used as pharmaceutical composition carrier for local antibiotic therapy of an acute or chronic infection of a tissue of a subject.
- Substrate for medical purposes, comprising a rifamycin and a coumarin antibiotic, particularly rifampin and novobiocin, characterised in that it is arranged and provided for being used as pharmaceutical composition carrier for local antibiotic therapy of an acute or chronic infection of a tissue of a subject.
- Substrate according to any of claims 25 to 27, characterised in that it comprises a fleece, a fabric, a polymethyl methacrylate, a copolymer of methylmethacrylate and methylacrylate, a biodegradable polymer, a metal, a ceramic, a bone cement and/or a bone substitute.
- Substrate according to claim 28, characterised in that the fleece or the fabric comprises a natural or synthetic fibre, particularly polylactide, and/or collagen.
- Substrate according to any of claims 25 to 29, characterised in that it is an implantable prosthesis, in particular a hip prosthesis, a shoulder prosthesis, an elbow prosthesis, a knee prosthesis or a vertebral implant or an implant for trauma surgery.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07075639A EP2018864A1 (en) | 2007-07-23 | 2007-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
US12/670,354 US8921365B2 (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
BRPI0814641-1A BRPI0814641A2 (en) | 2007-07-23 | 2008-07-23 | pharmaceutical composition, substrate comprising a pharmaceutical composition and use of a pharmaceutical composition. |
AU2008280485A AU2008280485B2 (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
JP2010517315A JP2010534213A (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising pharmaceutical composition, and use of pharmaceutical composition |
CN201410432991.0A CN104258374B (en) | 2007-07-23 | 2008-07-23 | The purposes of pharmaceutical composition, the matrix comprising pharmaceutical composition and pharmaceutical composition |
PCT/EP2008/006046 WO2009012986A1 (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
CA2694235A CA2694235C (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
CN200880100435A CN101765429A (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, comprise the purposes of the matrix and the pharmaceutical composition of pharmaceutical composition |
EP08784999A EP2173347A1 (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
KR1020107003575A KR20100043246A (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
US14/566,465 US9968710B2 (en) | 2007-07-23 | 2014-12-10 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
US15/951,804 US20180228941A1 (en) | 2007-07-23 | 2018-04-12 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07075639A EP2018864A1 (en) | 2007-07-23 | 2007-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2018864A1 true EP2018864A1 (en) | 2009-01-28 |
Family
ID=38680223
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07075639A Withdrawn EP2018864A1 (en) | 2007-07-23 | 2007-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
EP08784999A Withdrawn EP2173347A1 (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08784999A Withdrawn EP2173347A1 (en) | 2007-07-23 | 2008-07-23 | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
Country Status (9)
Country | Link |
---|---|
US (3) | US8921365B2 (en) |
EP (2) | EP2018864A1 (en) |
JP (1) | JP2010534213A (en) |
KR (1) | KR20100043246A (en) |
CN (2) | CN101765429A (en) |
AU (1) | AU2008280485B2 (en) |
BR (1) | BRPI0814641A2 (en) |
CA (1) | CA2694235C (en) |
WO (1) | WO2009012986A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015114452A3 (en) * | 2014-02-03 | 2015-11-12 | Biota Europe Ltd | Antibacterial combinations comprising polymyxin |
US10265330B2 (en) | 2012-06-29 | 2019-04-23 | Bayer Animal Health Gmbh | Pharmaceutical compositions and treatment of mastitis |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
US9931381B2 (en) * | 2009-11-23 | 2018-04-03 | Prothera, Inc. | Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
US20140072525A1 (en) * | 2012-09-07 | 2014-03-13 | Gaab, Llc | Antimicrobial preparation and methods for making and using the same |
US20160346354A1 (en) * | 2014-02-05 | 2016-12-01 | Reponex Pharmaceuticals Aps | Compositions to promote the healing of skin ulcers and wounds |
DE102014218913A1 (en) * | 2014-09-19 | 2016-03-24 | Heraeus Medical Gmbh | A process for producing an antibiotic polymethyl methacrylate bone cement powder and an antibiotic polymethyl methacrylate bone cement powder |
JP6631771B2 (en) * | 2015-05-11 | 2020-01-15 | 国立研究開発法人情報通信研究機構 | Microorganism analyzer and microorganism analysis method |
DE102015213855A1 (en) * | 2015-07-22 | 2017-01-26 | Biomet Deutschland Gmbh | Implant having a bioactive coating and method of making the same |
US10537661B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
US10537658B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
DE102019213178A1 (en) * | 2019-08-30 | 2021-03-04 | Resorba Medical Gmbh | Polymer film and polymer pouch for holding a medical-technical product to be implanted |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
WO2002032459A2 (en) * | 2000-10-17 | 2002-04-25 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
US20030153983A1 (en) * | 2002-02-08 | 2003-08-14 | Scimed Life Systems, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1068587A (en) | 1963-12-06 | 1967-05-10 | Biorex Laboratories Ltd | Dental fillers and bone cements comprising collagen |
DE2522081A1 (en) | 1975-05-17 | 1976-11-25 | Boehringer Mannheim Gmbh | ANTIBIOTICALLY EFFECTIVE PREPARATION |
FR2546406A1 (en) | 1983-05-27 | 1984-11-30 | Michaux Jean | Medical preparation for veterinary use, especially for lingual ulcers |
DE68926051T2 (en) | 1988-12-20 | 1996-08-29 | Jolla Cancer Res Found | POLYPEPTIDE-POLYMER CONJUGATES WITH Wounds Healing Effect |
GB9115901D0 (en) | 1991-07-23 | 1991-09-04 | Bradnock Brian R D | Improvements in antibiotic-containing acrylic beads |
US5407670A (en) * | 1993-01-28 | 1995-04-18 | Shinault; Wanda K. | Topical ointment for the treatment of epidermal trauma |
KR0139235B1 (en) * | 1994-01-29 | 1998-04-28 | 조세현 | Cement bead composition for orthopaedic surgery and its manufacturing process |
AUPM939694A0 (en) | 1994-11-11 | 1994-12-08 | University Of Sydney, The | Topical preparation |
US5624704A (en) * | 1995-04-24 | 1997-04-29 | Baylor College Of Medicine | Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent |
JPH09183730A (en) | 1995-05-10 | 1997-07-15 | Meiji Seika Kaisha Ltd | Medicine containing enantiomer of fosfomycin |
US5753702A (en) * | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
CA2301064A1 (en) | 1997-07-01 | 1999-01-14 | Brown University Research Foundation | Implantable prosthetic devices coated with bioactive molecules |
HUP0101716A3 (en) * | 1998-04-14 | 2003-01-28 | Jomaa Hassan | Use of organo phosphonic and phosphinic acid derivatives for producing medicaments useful for therapeutic and preventative treatment of infections |
KR20010070962A (en) * | 1998-07-15 | 2001-07-28 | 하싼 요마 | Phosphorous organic compounds and their use |
DE19843383A1 (en) | 1998-09-22 | 2000-03-30 | Hassan Jomaa | New amino and imino substituted organo-phosphorus compounds useful in medicine against viral, bacterial, fungal and parasiticidal infections and as herbicides, plant fungicides and plant bactericides |
NZ510690A (en) * | 1998-09-25 | 2002-10-25 | Cubist Pharm Inc | Methods for administration of antibiotics |
US6475434B1 (en) * | 1998-12-07 | 2002-11-05 | Baylor College Of Medicine | Composition and methods for preventing and removing biofilm embedded microorganisms from the surface of medical devices |
DE19859426A1 (en) | 1998-12-22 | 2000-07-06 | Hassan Jomaa | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections |
JP2002536974A (en) | 1999-01-21 | 2002-11-05 | アドバンスト・メディカル・ソリューションズ・リミテッド | Cell proliferation |
US6765000B2 (en) * | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
US6270347B1 (en) * | 1999-06-10 | 2001-08-07 | Rensselaer Polytechnic Institute | Nanostructured ceramics and composite materials for orthopaedic-dental implants |
RU2199978C2 (en) | 1999-10-12 | 2003-03-10 | Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии | Implant for surgical treatment of tubercular spondylitis |
WO2001034128A2 (en) | 1999-11-08 | 2001-05-17 | Pharmacia & Upjohn Company | Admixture for intravenous administration of linezolid and other antibacterial agents |
WO2001044272A2 (en) | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Daptomycin analogs as antibacterial agents |
BR0017028A (en) | 1999-12-15 | 2003-01-07 | Cubist Pharm Inc | Lipopeptides as antibacterial agents |
IL150225A0 (en) | 1999-12-15 | 2002-12-01 | Cubist Pharm Inc | Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof |
US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
GB2360789A (en) | 2000-03-30 | 2001-10-03 | Christopher Mason | Method of producing tissue structures |
AU2001253461A1 (en) | 2000-04-14 | 2001-10-30 | Orthopaedic Biosystems Ltd., Inc. | Coated anchoring device |
AU2001272935A1 (en) | 2000-05-31 | 2001-12-11 | Mayo Foundation For Medical Education And Research | Cobalamin compounds useful as antibiotic agents and as imaging agents |
US6719991B2 (en) | 2000-06-09 | 2004-04-13 | Baylor College Of Medicine | Combination of antimicrobial agents and bacterial interference to coat medical devices |
PE20020044A1 (en) | 2000-06-16 | 2002-01-30 | Upjohn Co | THIAZINE OXAZOLIDINONE |
US20060198815A1 (en) | 2001-03-19 | 2006-09-07 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
DE10119096A1 (en) | 2001-04-19 | 2002-10-24 | Keramed Medizintechnik Gmbh | New biologically functionalized coatings, useful for e.g. accelerating osteo-integration of implants, e.g. dental or joint implants, comprise resorbable calcium-phosphorus phase containing adhesion and/or signal proteins |
US20030236552A1 (en) | 2001-09-27 | 2003-12-25 | Roby Mark S. | Siliconized surgical needles and methods for their manufacture |
US20030065377A1 (en) * | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US20030194445A1 (en) * | 2001-11-12 | 2003-10-16 | Kuhner Carla H. | Compositions and methods of use of peptides in combination with biocides and/or germicides |
TW200403072A (en) | 2002-01-23 | 2004-03-01 | Upjohn Co | Combination therapy for the treatment of bacterial infections |
US7993390B2 (en) | 2002-02-08 | 2011-08-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US8133501B2 (en) * | 2002-02-08 | 2012-03-13 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
US8685427B2 (en) * | 2002-07-31 | 2014-04-01 | Boston Scientific Scimed, Inc. | Controlled drug delivery |
WO2003082248A2 (en) | 2002-04-03 | 2003-10-09 | Ranbaxy Laboratories Limited | Taste masked compositions of erythromycin a and derivatives thereof |
DE10262176B4 (en) | 2002-06-21 | 2007-10-04 | Heraeus Kulzer Gmbh | Process for the preparation of antibiotically coated porous bodies and use |
TW200403240A (en) | 2002-06-28 | 2004-03-01 | Upjohn Co | Difluorothioacetamides of oxazolidinones as antibacterial agents |
TW200404069A (en) | 2002-06-28 | 2004-03-16 | Upjohn Co | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent |
IL166156A0 (en) | 2002-07-09 | 2006-01-15 | Point Therapeutics Inc | Boroproline compound combination therapy |
US8920826B2 (en) * | 2002-07-31 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical imaging reference devices |
EP2407125A1 (en) | 2003-01-24 | 2012-01-18 | Tyco Healthcare Group, LP | Bioabsorbable composition and coatings including same |
CN1777653A (en) | 2003-04-18 | 2006-05-24 | 默克专利股份有限公司 | Antimicrobial pigments. |
US20060210500A1 (en) * | 2003-04-18 | 2006-09-21 | Merck Patent Gmbh | Formulations |
DE10333098A1 (en) | 2003-07-21 | 2005-02-10 | Blue Membranes Gmbh | New biocompatible, coated, implantable medicinal devices, e.g. stents, obtained by thermally carbonizing a polymeric coating, useful e.g. for controlled drug release |
WO2004101017A2 (en) | 2003-05-16 | 2004-11-25 | Blue Membranes Gmbh | Medical implants comprising biocompatible coatings |
DE10333099A1 (en) | 2003-07-21 | 2005-02-10 | Blue Membranes Gmbh | Medicinal implants, e.g. stents, with a functionalized surface, obtained by activating a carbon-containing coating to provide porosity then functionalizing, useful e.g. for controlled drug release |
DE10351150A1 (en) * | 2003-11-03 | 2005-05-25 | Blue Membranes Gmbh | Method and device for applying a defined amount of a coating material to the surface of a body to be coated |
JP4745340B2 (en) | 2004-05-17 | 2011-08-10 | コラス・フアーマ・インコーポレイテツド | Aerosolized fosfomycin / aminoglycoside combination for the treatment of bacterial respiratory infections |
DE102004060666B3 (en) | 2004-12-15 | 2006-03-30 | Heraeus Kulzer Gmbh | Antibiotic-containing bone substitute material comprises a compacted mixture of antibiotic-containing mineral granules and a binder |
US20060135546A1 (en) | 2004-12-16 | 2006-06-22 | Jagadevappa Basavaraja | Methods for the purification of 20(S)- camptothecin |
BRPI0517200A (en) | 2004-12-17 | 2008-09-30 | Venus Remedies Ltd | antibiotic combinations, processes of preparation of a combination of antibiotics and method of treatment |
DE102005002703C5 (en) | 2005-01-19 | 2013-07-04 | Heraeus Kulzer Gmbh | Antibiotic coating of implants and methods for antibiotic coating |
US7984717B2 (en) * | 2005-04-29 | 2011-07-26 | Medtronic, Inc. | Devices for augmentation of lumen walls |
US20060257444A1 (en) * | 2005-04-29 | 2006-11-16 | Medtronic, Inc. | Devices for augmentation of lumen walls |
US20060257445A1 (en) * | 2005-04-29 | 2006-11-16 | Medtronic, Inc. | Devices for augmentation of lumen walls |
US8003673B2 (en) | 2005-05-31 | 2011-08-23 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
US20070009564A1 (en) * | 2005-06-22 | 2007-01-11 | Mcclain James B | Drug/polymer composite materials and methods of making the same |
AU2006270221B2 (en) * | 2005-07-15 | 2012-01-19 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
ITRM20050393A1 (en) | 2005-07-22 | 2007-01-23 | Adele Bolognese | CONTROLLED RELEASE SYSTEM OF PHARMACOLOGICALLY ACTIVE SUBSTANCES, PROCESS OF PREPARATION AND USE IN MEDICAL FIELD. |
WO2007017019A2 (en) | 2005-07-28 | 2007-02-15 | Merck Patent Gmbh | Antimicrobial catheters |
KR101592659B1 (en) | 2005-10-07 | 2016-02-11 | 더 유니버시티 오브 알라바마 | Multi-functional ionic liquid composition for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients |
US20070093894A1 (en) * | 2005-10-25 | 2007-04-26 | Baylor College Of Medicine | Incorporation of antimicrobial combinations onto devices to reduce infection |
US20070134287A1 (en) * | 2005-12-09 | 2007-06-14 | Biomet Manufacturing Corp | Method for coating biocompatible substrates with antibiotics |
CN101365455A (en) * | 2005-12-15 | 2009-02-11 | 活跃生物药物学有限公司 | Uses of rifamycins |
US20070243237A1 (en) * | 2006-04-14 | 2007-10-18 | Mazen Khaled | Antimicrobial thin film coating and method of forming the same |
CA2661634C (en) | 2006-09-06 | 2017-03-28 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
EP2018857A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Medical device and use of a pharmaceutical composition |
-
2007
- 2007-07-23 EP EP07075639A patent/EP2018864A1/en not_active Withdrawn
-
2008
- 2008-07-23 US US12/670,354 patent/US8921365B2/en not_active Expired - Fee Related
- 2008-07-23 KR KR1020107003575A patent/KR20100043246A/en not_active Application Discontinuation
- 2008-07-23 EP EP08784999A patent/EP2173347A1/en not_active Withdrawn
- 2008-07-23 CA CA2694235A patent/CA2694235C/en not_active Expired - Fee Related
- 2008-07-23 CN CN200880100435A patent/CN101765429A/en active Pending
- 2008-07-23 WO PCT/EP2008/006046 patent/WO2009012986A1/en active Application Filing
- 2008-07-23 CN CN201410432991.0A patent/CN104258374B/en not_active Expired - Fee Related
- 2008-07-23 JP JP2010517315A patent/JP2010534213A/en active Pending
- 2008-07-23 BR BRPI0814641-1A patent/BRPI0814641A2/en not_active IP Right Cessation
- 2008-07-23 AU AU2008280485A patent/AU2008280485B2/en not_active Ceased
-
2014
- 2014-12-10 US US14/566,465 patent/US9968710B2/en not_active Expired - Fee Related
-
2018
- 2018-04-12 US US15/951,804 patent/US20180228941A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
WO2002032459A2 (en) * | 2000-10-17 | 2002-04-25 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
US20030153983A1 (en) * | 2002-02-08 | 2003-08-14 | Scimed Life Systems, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
Non-Patent Citations (13)
Title |
---|
FARBER B F ET AL: "SALICYLIC ACID PREVENTS THE ADHERENCE OF BACTERIA AND YEAST TO SILASTIC CATHETERS", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, vol. 27, no. 5, May 1993 (1993-05-01), pages 599 - 602, XP009011038, ISSN: 0021-9304 * |
GINALSKA ET AL: "Amikacin-loaded vascular prosthesis as an effective drug carrier", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 339, no. 1-2, 28 June 2007 (2007-06-28), pages 39 - 46, XP022133352, ISSN: 0378-5173 * |
HARRIS ET AL: "Staphylococci and implant surfaces: a review", INJURY, JOHN WRIGHT AND SONS, BRISTOL, GB, vol. 37, no. 2, May 2006 (2006-05-01), pages S3 - S14, XP005411019, ISSN: 0020-1383 * |
KANELLAKOPOULOU ET AL: "Comparative elution of moxifloxacin from Norian skeletal repair system and acrylic bone cement: an in vitro study", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, AMSTERDAM, NL, vol. 28, no. 3, September 2006 (2006-09-01), pages 217 - 220, XP005605464, ISSN: 0924-8579 * |
LEW D P ET AL: "Osteomyelitis", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 364, no. 9431, 24 July 2004 (2004-07-24), pages 369 - 379, XP004747135, ISSN: 0140-6736 * |
MERCURI ET AL: "Microbial Biofilms: A Potential Source for Alloplastic Device Failure", JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, SAUNDERS, PHILADELPHIA, PA, US, vol. 64, no. 8, August 2006 (2006-08-01), pages 1303 - 1309, XP005559651, ISSN: 0278-2391 * |
NORDEN C W ET AL: "CHRONIC STAPHYLOCOCCAL OSTEOMYELITIS: TREATMENT WITH REGIMENS CONTAINING RIFAMPIN", REVIEWS OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 5, no. SUPPL 3, July 1983 (1983-07-01), pages S495 - S501, XP009041854 * |
OCHIAI MINORU ET AL: "Clinical effect of arbekacin on MRSA infections after gastrointestinal surgery", JAPANESE JOURNAL OF ANTIBIOTICS, vol. 47, no. 6, 1994, pages 837 - 843, XP009092459, ISSN: 0368-2781 * |
RAMAGE G ET AL: "Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 24, no. 19, August 2003 (2003-08-01), pages 3221 - 3227, XP004425366, ISSN: 0142-9612 * |
RICHARDS ET AL: "Antiseptics and antibiotics on implants", INJURY, JOHN WRIGHT AND SONS, BRISTOL, GB, vol. 37, no. 2, May 2006 (2006-05-01), pages S113 - S116, XP005411033, ISSN: 0020-1383 * |
RODRIGUEZ-MARTINEZ ET AL: "P622 Penetration and activity of fosfomycin, ciprofioxacin, amoxicillin plus clavulanic acid and cotrimoxazol in Escherichia coli and Pseudomonas aeruginosa biofilms", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, AMSTERDAM, NL, vol. 29, March 2007 (2007-03-01), pages S145 - S146, XP022037815, ISSN: 0924-8579 * |
STALLMANN ET AL: "Antimicrobial peptides: review of their application in musculoskeletal infections", INJURY, JOHN WRIGHT AND SONS, BRISTOL, GB, vol. 37, no. 2, May 2006 (2006-05-01), pages S34 - S40, XP005411023, ISSN: 0020-1383 * |
ZEITLINGER M A ET AL: "Target site bacterial killing of cefpirome and fosfomycin in critically ill patients.", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 21, no. 6, June 2003 (2003-06-01), pages 562 - 567, XP002459419, ISSN: 0924-8579 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10265330B2 (en) | 2012-06-29 | 2019-04-23 | Bayer Animal Health Gmbh | Pharmaceutical compositions and treatment of mastitis |
WO2015114452A3 (en) * | 2014-02-03 | 2015-11-12 | Biota Europe Ltd | Antibacterial combinations comprising polymyxin |
Also Published As
Publication number | Publication date |
---|---|
US20180228941A1 (en) | 2018-08-16 |
KR20100043246A (en) | 2010-04-28 |
AU2008280485A1 (en) | 2009-01-29 |
CA2694235C (en) | 2013-12-03 |
CN101765429A (en) | 2010-06-30 |
US8921365B2 (en) | 2014-12-30 |
CA2694235A1 (en) | 2009-01-29 |
US20100216697A1 (en) | 2010-08-26 |
AU2008280485B2 (en) | 2011-09-15 |
JP2010534213A (en) | 2010-11-04 |
US9968710B2 (en) | 2018-05-15 |
US20150157766A1 (en) | 2015-06-11 |
EP2173347A1 (en) | 2010-04-14 |
BRPI0814641A2 (en) | 2019-03-12 |
CN104258374B (en) | 2018-12-07 |
WO2009012986A1 (en) | 2009-01-29 |
CN104258374A (en) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9968710B2 (en) | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition | |
Campoccia et al. | Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use | |
JP6626834B2 (en) | Antibacterial article manufactured by additive manufacturing method | |
JP5254207B2 (en) | Antibacterial composition | |
US20110082545A1 (en) | Drug eluting breast implant cover or coating | |
JP2006507850A5 (en) | ||
US9381281B2 (en) | Drug eluting mesh to prevent infection of indwelling transdermal devices | |
US20070015685A1 (en) | Bone cement compositions and the like comprising an RNAIII-inhibiting peptide | |
Harrison et al. | In vitro evaluation of loaded chitosan membranes for pain relief and infection prevention | |
WO2009013024A1 (en) | Medical device and use of a pharmaceutical composition | |
US20150328377A1 (en) | Composition of d-alpha hydroxy acids and antimicrobials | |
US20190015385A1 (en) | Vitamin e phosphate or acetate for use in the treatment and prevention of biofilm infections | |
Kühn | Antimicrobial implant coating | |
Romanò et al. | Antibiofilm Strategies in Orthopedics: Where Are We? | |
Kühn | Coating | |
Harris | Evaluation of Phosphatidylcholine as a Local Drug Delivery Device for Application to Orthopedic Implants | |
Smith et al. | Infection-resistant implantable devices: Biofilm problems and design strategies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
AKX | Designation fees paid | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090129 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |